?

Bradner James E.

EVP, R&D, & Chief Sci. Officer
Amgen Inc.
US, Thousand Oaks [HQ]
CIK 2005159

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

Shares :
25,438
Price per Share :
$272.11
Equivalence :
$6,921,934.18

Transaction History

  • 25,438 Shares After Transaction
    Value : $n/a
    $0.0
    05/07/24
  • Footnotes:
    #1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.
    #2 These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028; and 2,863 RSUs which will vest in installments of 944 on 5/7/2026, 945 on 5/7/2027, and 974 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
    #3 These shares include 182 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
  • 8,587 Shares After Transaction
    Value : $n/a
    $0.0
    02/09/24
  • 22,393 Shares After Transaction
    Value : $n/a
    $0.0
    02/09/24